This trial is testing a new drug, TL-895, to see if it is safe and tolerable for people with relapsed or refractory B cell malignancies who have failed one to three prior therapies. The trial has two parts; the first part has already completed testing and the second part is currently enrolling participants. The second part of the trial will test different doses of TL-895 on two groups of people: those who have failed at least one prior therapy, and those who have not received any prior therapy. Every participant in the study will receive TL-895.